StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Research analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Sunday. The firm set a “sell” rating on the stock.

Separately, Maxim Group lowered their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 12th.

Moleculin Biotech Trading Down 11.8 %

NASDAQ:MBRX opened at $0.70 on Friday. Moleculin Biotech has a 1-year low of $0.66 and a 1-year high of $10.35. The company’s 50-day moving average is $1.84 and its two-hundred day moving average is $2.30.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.